OptimizeRx Reports Third Quarter 2026 Financial Results and Updates Fiscal Year 2026 Guidance
Q3 revenue totals $21.6 millionQ3 net income and adjusted EBITDA of $1.2 million and $6.3 million2026 revenue guidance updated to $87-$93 million; adjusted EBITDA guidance unchanged at $21-$25 millionRepaid $9.3 million in debt principal since June… Read More »OptimizeRx Reports Third Quarter 2026 Financial Results and Updates Fiscal Year 2026 Guidance
